



डॉ. राजीव बहल, एमडी, पीएचडी
DR. RAJIV BAHL MD, PhD



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH

सचिव, भारत सरकार
स्वास्थ्य अनुसंधान विभाग
स्वास्थ्य एवं परिवार कल्याण मंत्रालय एवं
महानिदेशक
भारतीय आयुर्विज्ञान अनुसंधान परिषद
Secretary, Government of India
Department of Health Research
Ministry of Health & Family Welfare
Director-General
Indian Council of Medical Research

INDO/FRC/649/10-IHD
Dated: 10th October, 2025

Sub: Renewal of the Memorandum of Understanding (MoU) signed between ICMR and DNDi

Dear Dr. Pizarro,

Thanks for your letter and the proposed extension of the Memorandum of Understanding (MoU) signed on 15th October, 2015 between ICMR and DNDi for cooperation in neglected diseases for a period of 5 years.

ICMR and DNDi have worked towards building up of a strong relationship in the area of neglected and vector-borne diseases.

The proposed extension of MoU by DNDi is acceptable to ICMR along with the 1 additional area of research.

1. Drug Discovery and development towards Pandemic Preparedness.


As per clause 6 (Term) of the original MoU, the ICMR conveys its approval to extend the provisions of the 2015 ICMR-DNDi MoU which will be in effect for successive five years from the date of its expiry i.e. 15th October, 2025. The jointly agreed upon and duly signed statement indicating the above mentioned one additional point shall enter into force on 15th October, 2025 as an Appendix to the original MoU.

Once the extension of the MoU is established through our exchange of letters and signing of the statement, the implementing agencies, modes of cooperation and other provisions will remain the same as stated in the 2015 MoU throughout the extension period i.e. till 15th October, 2030. For reference, a copy of the MoU signed in 2015 MoU is attached.

Two original copies of the statement duly signed by me are attached, an original copy of which may please be returned to us after your signature.


We look forward to hearing from you and to the continuation of this bilateral collaboration. We also deeply appreciate your continued leadership and commitment to this program.

Best regards,



Dr. Luis Pizarro
Executive Director
Drugs for Neglected Diseases initiative (DNDi)
Chemin Louis Dunant 15, 1202 Geneva, Switzerland

Yours sincerely,



(Dr. Rajiv Bahl)

Enclosures:

1. Two copies of the statement on renewal of ICMR-DNDi MoU
2. A copy of the ICMR-DNDi MoU signed in October, 2015

Renewal of the Memorandum of Understanding

between

Indian Council of Medical Research, (ICMR)

and

Drugs for Neglected Diseases Initiative (DNDi)

STATEMENT


The ICMR-DNDi Memorandum of Understanding signed on 15th October, 2015 is hereby renewed as per clause 6 (Term) of the 2015 ICMR-DNDi MoU and extend its provisions which will be in effect for the successive five years from the date of its expiry i.e. 15th October, 2025

We here agree to cooperate and include the one additional area of research during the extended duration of the MoU which shall enter into force on 15th October, 2025.

1. Drug Discovery and development towards Pandemic Preparedness.


All terms and conditions such as the implementing agencies, modes of cooperation and other provisions as agreed upon under the ICMR-DNDi MoU signed in 2015 shall remain the same and will be followed by both the Parties throughout the extension period till 15th October, 2030.

For the ICMR



Dr. Rajiv Bahl
Director General
Indian Council of Medical Research

For the DNDi



Dr. Luis Pizarro
Executive Director
Drugs for Neglected Diseases Initiative

Date 10/10/25

Date 13/10/2025

